Gain Therapeutics Inc. (GANX)
NASDAQ · Healthcare
Gain Therapeutics Inc. EBITDA 2020–2023
Gain Therapeutics Inc. annual/quarterly ebitda history and growth rate from 2020 to 2023. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Gain Therapeutics Inc. ebitda for the quarter ending March 31, 2023 was -5.2 M, a 58.85% increase year-over-year.
- Gain Therapeutics Inc. ebitda for the twelve months ending March 31, 2023 was -11.5 M.
- Gain Therapeutics Inc. annual ebitda for 2023 was -22.2 M, a 25.16% increase from 2022.
- Gain Therapeutics Inc. annual ebitda for 2022 was -17.7 M, a 28.25% increase from 2021.
- Gain Therapeutics Inc. annual ebitda for 2021 was -13.8 M, a 298.02% increase from 2020.
- Gain Therapeutics Inc. annual ebitda for 2020 was -3.5 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
Gain Therapeutics Inc. EBITDA — FAQ
Gain Therapeutics Inc. (GANX) ebitda over the last 4 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see GANX's ebitda history?
The chart and table above show Gain Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.